Health Hive: The AI Data Infrastructure Layer for "Infinite Healthcare"
We are a B2B2C marketplace turning fragmented medical records into a high-yield asset for patients, and high-fidelity, longitudinal training data for enterprise AI.
The "Hair on Fire" Problem: The AI Data Wall
Healthcare AI development has hit the "Data Wall." Foundational models can no longer simply scrape the internet—they need secure, HIPAA-protected health records. Existing data brokers sell fragmented, anonymized snapshots that lack the longitudinal depth (tracking a patient's outcomes over time) required to train highly capable, predictive medical AI.
The Incentive Breakthrough (Our Wedge)
To secure deep, continuous, granular data (Genomics, EHR, Wearables, Daily Symptoms), we aligned incentives.
By transparently sharing 50% of net leasing revenue directly with the patient and providing them with a world-class "Health OS" app, we transform privacy apprehension into eager participation. We guarantee compliant, patient permitted data with explicit consumer opt-in, solving the hardest problem in healthcare data acquisition.
The Defensible Moat: Our Flywheel
Our B2B2C model creates an unbreachable network effect governed by Data Gravity.
1. Supply Aggregation
Consumer utility (Medical Passport) and passive income promise drives rapid user acquisition at an exceptionally low CAC.
2. Enterprise Demand
A richer, highly specific dataset attracts top Pharma and AI developers, commanding premium enterprise lease contracts.
3. Yield Generation
Higher enterprise demand drives up the patient's monthly dividend yield, accelerating organic referrals and lowering CAC further.
The Clinical Value Proposition
For the Patient: The Ultimate "Health OS"
Beyond the financial dividend, Health Hive acts as a comprehensive one-stop shop. Users effortlessly aggregate, track, and manage their entire healthcare journey in a single interface. By leveraging their portable Medical Passport, patients eliminate the friction of siloed portals and experience significantly improved, deeply coordinated care across any health system they visit.
For the Provider: Supercharging Clinical Care
Clinicians are no longer forced to treat patients with blind spots. When a patient shares their Medical Passport, the provider instantly accesses a unified, longitudinal record—including out-of-network diagnostics, active prescriptions, and daily wearable data. This eliminates administrative waste, prevents adverse medical events, and drives highly precise, data-backed treatment at the point of care.
Total Addressable Market
TAM: AI in Healthcare
$1.5TSAM: Health Data Licensing
$150BSOM: Real-World Evidence
$12BPath to a $10B+ Outcome
Launch Round. Proving the supply-side incentive model and deploying the V2 Secure Sandbox to early enterprise design partners.
Scale Phase. Crossing $50M ARR. Established as the standard for oncology and rare disease Real-World Evidence (RWE).
Pre-IPO Crossover Round. Crossing $100M ARR with 135% Net Revenue Retention (NRR) from top 20 Pharma.
Public Offering. Operating as the de facto "Data OS" for all global healthcare AI training and validation.
$50M Growth Round & Scenarios
Current Pre-Money Valuation: $200M. Capital allocation designed to dominate the supply side (users) and lock in enterprise demand, achieving cash-flow positive operations within 28 months.
Uses of Funds & Growth Milestones
This $50M injection is engineered to reach $100M+ ARR, establishing Health Hive as the undeniable category leader ahead of a pre-IPO crossover round.
- Scale to 1,000,000 Active Users via direct consumer marketing and B2B2C API partnerships.
- Secure 15 Enterprise AI/Pharma Contracts at a target ACV of >$1.5M each.
- Launch V2 of Secure Compute Sandbox with native Jupyter notebook and direct cloud-bucket integrations.
Target Unit Economics
Because we operate on a revenue-share model with patients rather than paying massive upfront data acquisition fees, our unit economics display SaaS-like Gross Margins (80%+).
- CAC Payback Period: < 6 Months
- Cash Runway: 36 Months
- Break-Even Target: Month 28 (Year 3, Q1)
Financial Trajectory Scenarios (Cash Flow / Burn)
Base Case
Targeted enterprise adoption and stable $45 CAC. Break-even at Month 28.
Bull Case
Viral consumer loop drops CAC to $20. Break-even at Month 22.
Bear Case
Slower B2B sales cycles & higher consumer CAC ($75). Break-even at Month 40.
Execution Roadmap
A granular 36-month plan aligning cash burn with value-creation milestones, driving to $120M ARR and break-even at Month 28.
The 180-Day Sprint (Months 1-6)
Month 1: Core Assembly
- Execute agreements for C-Suite (CFO, COO, CMO).
- Provision zero-trust AWS/GCP secure enclaves.
- Launch waitlist with "Enterprise Value Shares" equity hook.
Month 2: App V1 Finalization
- Onboard FHIR Integration Engineers (x3) and Senior SecOps.
- Finalize V1 of the Consumer "Health OS" App (EHR + Wearable aggregation).
- Begin pre-selling discounted Sandbox access to AI startups.
Month 3: Security & Beta
- Complete third-party white-hat penetration testing ($800k allocation).
- Onboard first 5,000 beta users from waitlist in select high-value cohorts.
- Secure 5 Letters of Intent (LOIs) from CROs for aggregate data queries.
Month 4: Public Launch
- Official Public Launch. Initiate the "Mass-Market Utility" playbook.
- Deploy V1 Secure Compute Sandbox for B2B clients.
- Convert 5 CRO LOIs into paying Sandbox contracts (Initial MRR begins).
Month 5: AI Co-Pilot & Viral Loops
- Launch the Live AI Health Co-Pilot feature (Claude/OpenAI API integration).
- First massive viral loop—users share their "Medical Passport" and pool family dividends.
- Outreach to mid-market payers/insurers for RWE syndication.
Month 6: Value Creation
- Milestone: Integrate 5 top consumer wearables (Apple, Oura, Dexcom).
- First quarter cash dividends distributed. Users post earnings, dropping CAC to near-zero.
- Close first $500k ACV clinical trial matching bounty.
The 36-Month Scale Plan
Year 1: The Mass-Market Wedge & Agile AI Revenue (Months 7-12)
Goal: 100,000 Active Users | $15M Gross ARR | Prove the Zero-CAC Viral Loop
- Month 7: Begin TEFCA Node integration. Launch VBC Enablement sales motion targeting ACOs.
- Month 8: Roll out the "Data Philanthropy" auto-routing feature. Sign first 2 VBC optimization contracts.
- Month 9: V2 Sandbox live. Initiate "Land" motion with Top 20 Global Pharma: offering 30-day freemium sandbox pilots.
- Month 10: Alpha launch of the Hive Consent API. 5 Big Pharma companies actively running free pilots.
- Month 11: FDA PCCP frameworks established for AI matching algorithms. Convert first Big Pharma pilot into paid, multi-year lease ($1M+ ACV).
- Month 12: Cross 100,000 Active Users and hit $15M Gross ARR target.
Year 2: The API Flywheel & Enterprise Expansion (Months 13-24)
Goal: 350,000 Active Users | $45M Gross ARR | Achieve 135% NRR
- Month 13: Public release of the Hive Consent API. B2C marketing spend is scaled back as third-party apps begin onboarding users.
- Month 16: TEFCA Node integration goes live. Health Hive can instantly query nationwide EHR networks for consented users.
- Month 17: Launch Genomic Data Parsing Engine.
- Month 19: Shift Enterprise Sales to "Expand." Upsell existing Big Pharma clients from static data queries to real-time FHIR streaming API integration.
- Month 21: Roll out Beta of the Privacy-First Precision Ad Network to MedTech hardware partners.
- Month 24: Cross 350,000 Active Users. Hit $45M Gross ARR target. Burn rate dramatically decreases as gross margins stabilize.
Year 3: Absolute Lock-In & Profitability (Months 25-36)
Goal: 1,000,000 Active Users | $120M Gross ARR | Cash-Flow Positive
- Month 25: Full public rollout of Privacy-First Ad Network.
- Month 27: Financial Milestone: Operational break-even point. We are now funding our own growth.
- Month 28: Deploy advanced AI cross-referencing engine. Selling 3D Data (EHR + Wearables + Genomics) at an extreme premium.
- Month 31: Achieve 135% NRR across Top 20 Pharma. Health Hive is structurally embedded into their R&D pipelines.
- Month 33: Launch the Hive "Algorithm Marketplace," allowing AI developers to sell trained health algorithms back to consumers.
- Month 36: Hit 1,000,000 Active Users and $120M Gross ARR. Close Pre-IPO Crossover round, valuing the enterprise at a 15x-20x infrastructure multiple.
Financial Engine (T2D3 Trajectory)
Projected revenue, costs, and margins mapped to the elite "Triple, Triple, Double, Double, Double" SaaS growth curve expected by tier-1 VCs.
Projected Gross ARR Growth ($M)
Achieving 300%+ YoY Growth
Unit Economics at Scale (Per User, Year 3 Projection)
5-Year P&L Scenarios
Base Case: Standard Enterprise Adoption (T2D3 Trajectory)
| Metric | Year 1 | Year 2 | Year 3 | Year 5 |
|---|---|---|---|---|
| Active Users | 100,000 | 350,000 | 1,000,000 | 4,500,000 |
| Gross Revenue | $15,000,000 | $45,000,000 | $120,000,000 | $500,000,000 |
| Patient Dividends (50% of Net) | ($6,500,000) | ($20,000,000) | ($55,000,000) | ($235,000,000) |
| Net Revenue (Company Share) | $8,500,000 | $25,000,000 | $65,000,000 | $265,000,000 |
| OpEx & Infrastructure | ($12,200,000) | ($18,000,000) | ($28,000,000) | ($85,000,000) |
| EBITDA | ($3,700,000) | $7,000,000 | $37,000,000 | $180,000,000 |
*Note: Platform Gross Margins (excluding patient dividends) target the 75% - 85% range characteristic of software native companies.
Bull Case: Viral Consumer Growth & Premium ACV
| Metric | Year 1 | Year 2 | Year 3 | Year 5 |
|---|---|---|---|---|
| Active Users | 150,000 | 600,000 | 2,000,000 | 10,000,000 |
| Gross Revenue | $25,000,000 | $85,000,000 | $260,000,000 | $1.2B |
| Patient Dividends (50% of Net) | ($11,500,000) | ($38,000,000) | ($120,000,000) | ($565,000,000) |
| Net Revenue (Company Share) | $13,500,000 | $47,000,000 | $140,000,000 | $635,000,000 |
| OpEx & Infrastructure | ($14,000,000) | ($22,000,000) | ($35,000,000) | ($120,000,000) |
| EBITDA | ($500,000) | $25,000,000 | $105,000,000 | $515,000,000 |
Bear Case: Slower Enterprise Cycles
| Metric | Year 1 | Year 2 | Year 3 | Year 5 |
|---|---|---|---|---|
| Active Users | 75,000 | 200,000 | 450,000 | 1,500,000 |
| Gross Revenue | $10,000,000 | $25,000,000 | $50,000,000 | $150,000,000 |
| Patient Dividends (50% of Net) | ($4,500,000) | ($11,000,000) | ($22,000,000) | ($68,000,000) |
| Net Revenue (Company Share) | $5,500,000 | $14,000,000 | $28,000,000 | $82,000,000 |
| OpEx & Infrastructure | ($10,000,000) | ($15,000,000) | ($22,000,000) | ($50,000,000) |
| EBITDA | ($4,500,000) | ($1,000,000) | $6,000,000 | $32,000,000 |
The Data Value Curve
In healthcare AI, data value does not scale linearly with user count; it scales exponentially with dimensionality (Metcalfe's Law applied to health data).
1D Data: Single Source
Example: EHR Records only.
Highly commoditized. Tells you what happened in the clinic, but misses 99% of the patient's actual life. Low margin, high competition.
2D Data: Correlated
Example: EHR + Daily Wearables.
Predictive value unlocks. We can now correlate an asthma attack in the EHR to daily heart rate variability drops days prior.
3D Data: The Holy Grail
Example: EHR + Wearables + Genomics + Patient Reported Outcomes.
Exponential value. AI can now isolate precise genetic markers responding to specific lifestyle interventions.
Metcalfe’s Law of AI Training
Why 1 million patients with 5 data sources each is worth 100x more than 1 million patients with 1 data source.
The Cross-Referencing Moat
Our platform allows enterprise researchers to perform high-dimensional cross-referencing that is mathematically impossible on legacy platforms. For instance, finding the correlation between a specific genetic marker, a daily heart rate variability trend, and a clinical asthma exacerbation becomes visible only at massive scale and high dimensionality. As our users connect more apps (Oura, Dexcom, 23andMe) via our API, the value of the Hive compounds automatically without additional CAC.
Regulatory & Technical Moat
Investors prioritize Applied AI that integrates seamlessly with existing healthcare tech stacks while meeting stringent regulatory requirements.
TEFCA & Interoperability
TEFCA has become the national standard for healthcare data exchange. Health Hive is "TEFCA-ready," utilizing FHIR R4 APIs and standardized datasets like USCDI v7 to ensure seamless data liquidity. This alignment is a strategic asset that reduces administrative burden.
FDA AI Governance
The FDA’s "Predetermined Change Control Plan" (PCCP) allows us to pre-specify modifications to our AI algorithms, enabling continuous improvement without a new 510(k) submission. Mastery of these "living systems" pathways creates a powerful Regulatory Moat.
Cybersecurity Protocols
The updated HIPAA Security Rule mandates MFA and encryption at rest/transit. We meet these standards with a "Zero-Trust" architecture, and provide a Software Bill of Materials (SBOM) to ensure supply chain security.
Regulatory Standards Matrix
| Regulatory Pillar | Legacy Requirement | Modern Standard for Investment |
|---|---|---|
| Interoperability | Ad-hoc API connections | TEFCA / QHIN Alignment |
| AI Governance | Static validation studies | PCCP (Predetermined Change Control) |
| Cybersecurity | "Addressable" Safeguards | Mandatory MFA, Encryption, SBOM |
| Data Standards | Non-standardized JSON | USCDI v7 / FHIR R4 |
Valuation & Exit Path
Valuation models based on Data Infrastructure multiples governed by "Data Gravity."
The "Data Gravity" Thesis
As AI models become commoditized, proprietary data becomes the only true differentiator. Health Hive is building the ultimate data monopoly. Data Gravity dictates that large, high-fidelity datasets attract the most applications and services. We are not just a SaaS tool; we are the foundational infrastructure for the next decade of medical AI. This commands infrastructure-level multiples (15x - 20x Forward ARR).
Path to a $10B+ Outcome
Strategic Launch Round. Proving the supply-side incentive model and deploying the V2 Secure Sandbox to early enterprise design partners.
Expansion Phase. Crossing $50M ARR. Established as the standard for oncology and rare disease Real-World Evidence (RWE).
Pre-IPO Crossover Round. Crossing $100M ARR with 135% Net Revenue Retention (NRR) from top 20 Pharma.
Public Offering. Operating as the de facto "Data OS" for all global healthcare AI training and validation.
Market Comparables & Competitive Moat
Health Hive operates in a crowded market. To attract top-tier VCs, we differentiate from incumbents while out-innovating newer AI-first platforms.
Category 1: Health Tech 1.0 (Legacy)
These firms carry "technology debt" and less efficient unit economics. Health Hive’s advantage lies in being an AI-native platform integrating healthcare consumerism with financial planning.
Point solutions rather than broader infrastructure.
Category 2: Legacy Data Aggregators
The leader in health data tokenization, connecting disparate datasets for life sciences without exposing identities.
Their Weakness: They operate without direct patient consent or compensation, exposing them to massive regulatory risk.
Offers micro-rewards (points) to users for taking surveys.
Their Weakness: An opaque "points" system leads to high churn. They lack deep integration with longitudinal EHR systems.
The Hive Advantage Matrix
| Investment Factor | Health Tech 1.0 (Legacy) | Health Hive (Modern Standard) |
|---|---|---|
| Primary Goal | Access and Virtualization | Outcomes and Efficiency |
| AI Role | Experimental Feature | Core Operating Engine |
| Growth Curve | Linear (Personnel-Dependent) | Exponential (AI-Driven Velocity) |
| Margin Profile | 40% - 60% (Services Heavy) | 70% - 80%+ (Software Native) |
Deep Dive: Comps & Growth Trajectories
A granular look at the data acquisition mechanisms of the closest institutional precedents, contrasted against emerging consumer AI, mapping why Health Hive's patient permitted consent model is structurally superior.
Market Positioning: The Consent Gap
Legacy aggregators built enterprise scale without explicit consumer permission. Emerging AI apps built consumer permission without enterprise monetization. Health Hive sits directly in the highly lucrative intersection.
Revenue Growth Trajectories (Years 0-5)
Comparing legacy enterprise EHR scaling (Epic), M&A-driven tokenization (Datavant), B2C AI health coaching (Nori.ai), and Health Hive's projected T2D3 path.
Competitive Mechanics Breakdown
1. Epic (Cosmos)
The largest EHR vendor in the US, leveraging its massive provider network to build Cosmos, a research database of >200M patients.
- Data Gathering: Sweeps data from participating health systems using their software.
- Monetization: Indirect. Used to add value to hospital customers and retain ecosystem dominance.
- Permissions: Institutional BAAs and Governance councils. Relies on broad, de-identified exemptions.
- The Gap: Siloed to Epic providers. No wearables, no out-of-network data. Lacks explicit individual consent for commercial AI training.
2. HealthVerity
A massive B2B Real-World Data (RWD) ecosystem aggregating claims, labs, and EHRs across 340M+ patients.
- Data Gathering: B2B marketplace. Institutions plug in fragmented data silos.
- Monetization: Licenses data subscriptions to pharma and government agencies.
- Permissions: HIPAA Expert Determination (De-Identification) Safe Harbor.
- The Gap: Zero patient relationship. They cannot ethically or legally re-contact a patient if a clinical trial match is found.
3. Datavant / Ciox
The underlying plumbing of health data. A $7B+ tokenization engine that securely matches patient records across institutions.
- Data Gathering: Installs tokenization software behind hospital firewalls to link existing data.
- Monetization: Software licensing and transactional linkage fees.
- Permissions: Institutional BAAs.
- The Gap: They do not own the data, they only own the pipes. They are completely disconnected from the actual patient generating the data.
4. Nori.ai (The B2C AI Coach)
A YC-backed (F25) startup representing the next generation of consumer AI. Nori aggregates wearables, labs, and EHRs to act as an automated personal health advisor.
- Data Gathering: Direct consumer OAuth integrations (Apple Health, Oura, Whoop, MyChart, Lab tests).
- Monetization: B2C Freemium and Pro Subscription models.
- Permissions: Explicit patient permitted consent; utilizes "HealthMCP" to securely pipe data to AI models.
- The Gap: Highly focused on B2C personal utility, completely missing the massive B2B enterprise data monetization engine. Users pay to use the AI, but earn nothing from their highly valuable underlying data.
The Health Hive Edge: Patient Permitted Data
The legacy platforms (Epic, Datavant, HealthVerity) rely entirely on institutional loopholes—de-identifying data so they don't have to ask the patient for permission. This strips the data of its most valuable utility: the ability to longitudinally track and re-engage the patient.
Complete Fidelity
By acquiring direct, explicit consent, we bridge the gap. We connect the Epic hospital record with the out-of-network clinic, the at-home Oura ring data, and the 23andMe genetics.
Trial Re-Contact
Because we have the patient's explicit permission, when our AI matches their de-identified profile to a life-saving clinical trial, we can legitimately reach out and recruit them.
Enterprise Data Leasing
While B2C AI tools like Nori effectively aggregate data for personal coaching, they leave the most lucrative table stakes behind: enterprise monetization. By aligning economic incentives (the 50/50 split), we don't charge users—we pay them, generating a willing data supply chain for multi-billion dollar Pharma/CRO research.
U.S. Healthcare Data Precedent Set
A structured comparison of how legacy unicorns utilized data vs. Health Hive's patient permitted consent model.
| Company / Valuation | Data Utilization (How They Used Data) | Core Limitation / Risk | The Health Hive Edge |
|---|---|---|---|
| Flatiron Health $1.9B Acquisition |
Extracted data from oncology EHRs to build regulatory-grade RWE cohorts for pharma. | Siloed to oncology and dependent on massive manual chart abstraction costs. | Patient-centered aggregation spans all therapeutics with automated FHIR ingestion. |
| Tempus AI ~$9B Market Cap |
Sequences genomic tests and pairs them with clinical data to train precision medicine AI. | Extremely capital intensive; reliant on proprietary, expensive lab testing hardware. | Zero hardware cost. Aggregates existing genomics (23andMe) and clinical data natively. |
| Truveta $1B+ Valuation |
Pools de-identified EHR data from 30+ health systems to offer daily-updated research sets. | Lacks direct patient consent and loses visibility when patients visit out-of-network clinics. | Follows the patient everywhere. Captures out-of-network care, OTC meds, and wearables. |
| Datavant / Ciox $7B Merger |
Uses tokenization to link de-identified datasets across different silos without exposing PII. | Only links what already exists in silos. No direct consumer engagement or utility. | Generates net-new, highly correlated 3D datasets (EHR + Wearables) with explicit consent. |
| HealthVerity $100M Series D |
Operates a B2B marketplace to license and exchange de-identified RWD using a governance layer. | Highly competitive B2B RWD market with no moat on the actual patient relationship. | Owns the primary consumer relationship via the Health OS, ensuring future-proof consent. |
| PicnicHealth $60M Series C |
Manually retrieves and digitizes medical records for patients, then sells disease-specific cohorts. | Manual retrieval and curation is a unit-economic death trap limiting scale. | Leverages TEFCA and APIs to automate retrieval, dropping CAC and curation costs to near-zero. |
| Evidation $153M Series E |
Collects continuous wearable/behavioral data via a rewards app and sells cohort access. | Data lacks deep clinical fidelity (mostly surveys and basic wearable stats). | Pairs behavioral data with cryptographically verified, longitudinal EHR and lab records. |
| 23andMe Chapter 11 (2025) |
Sold DTC DNA tests, asked for research consent, and licensed the genetic database to pharma. | Lost consumer trust; data sale triggered massive national security/privacy alarms. | Privacy enforced by math. No raw data is ever exported; buyers lease secure compute access. |
| LunaDNA Shut Down (2024) |
Allowed users to upload DNA and health data in exchange for SEC-qualified shares. | Crushed by securities friction and lacked any daily utility to drive engagement. | Leads with a daily Health OS utility. Financial dividends are a frictionless byproduct. |
Go-To-Market & Consumer Acquisition
A hyper-sequenced roadmap to bypass the "Cold-Start Problem". We study historical enterprise supply acquisition and execute a highly targeted consumer marketing budget.
Engine 1: Supply Side
Acquiring 1M+ Patients (Data Generation)
Months 0-12 Mass-Market Utility & Equity Wedge
We target the general public by solving a universal pain point: fragmented health records. By offering a unified "Health OS", we drive organic adoption. The viral loop is supercharged by offering early adopters a direct stake in the AI value chain through Enterprise Value Shares.
Months 6-18 High-Growth Niches
Targeting historically under-invested sectors: Women's Health (fertility, menopause) and Longevity. These communities exhibit high engagement and willingness to share data for medical advancement.
Months 12-24 B2B2C Embedded API
Inspired by Plaid. We stop acquiring users directly and let existing apps do it for us. Digital health apps embed our "Monetize Your Data" API. The app takes a 10% rev-share, the patient gets 50%, and Health Hive scales passively.
Engine 2: Demand Side
Hacking the Enterprise Sales Cycle
Months 0-12 Agile AI & CROs
To generate immediate cash flow, we target well-funded Health-AI startups and Contract Research Organizations (CROs). We offer them frictionless, self-serve access to our secure compute sandboxes.
Months 12-24 VBC Enablement
We license predictive datasets to risk-bearing organizations (ACOs, CINs) operating under Value-Based Care (VBC) to help them optimize Medical Loss Ratios (MLR) and CMS Star Ratings.
Months 18-36+ Big Pharma Land & Expand
Targeting Top 20 Pharma with a 30-day freemium pilot to prove data fidelity. Once validated, we "Expand" by locking them into multi-year cohort leases ($500k+ ACV), driving Net Revenue Retention past 135%.
Lessons from Precedent Supply Roadmaps
How did the $1B+ legacy aggregators get their data supply? And how do we bypass their bottlenecks?
- The Datavant Method (M&A): They acquired Ciox Health for billions just to get access to the physical medical record retrieval infrastructure. Hive Solution: By building directly on modern FHIR APIs and TEFCA, we bypass billions in M&A costs to aggregate records digitally.
- The Epic Method (SaaS Lock-in): They gave away Cosmos access to hospitals as a perk for using their multi-million dollar EHR software. Hive Solution: We flip the model, giving away the Health OS app to consumers for free, locking in supply via utility and financial dividends.
- The Evidation Method (Consumer Rewards): Paid users pennies for stepping. Scaled to 5M+ users. Hive Solution: Elevate the reward from "points" to actual enterprise revenue-sharing, creating a far stickier, high-fidelity user base.
Consumer Acquisition: Budgets & Execution
A granular breakdown of the $17.5M allocated for Consumer CAC & Marketing over the next 24 months to reach 1,000,000 active users.
Phase 1: Seed & Establish
$2.0M Months 1-6Focus: Acquiring the first 50,000 high-acuity users (Rare Disease, Oncology) where data value is highest.
- Hiring: Chief Marketing Officer (CMO) / VP of Growth.
- Agency: Retain top-tier performance marketing firm for initial message testing.
- Tactic: Paid partnerships with Patient Advocacy Groups & foundational waitlist seeding.
Phase 2: Viral Velocity
$5.0M Months 7-12Focus: Scaling to 250,000 users by optimizing organic referral loops and influencer channels.
- Hiring: Bring media buying in-house. Hire Community Managers for specific disease cohorts.
- Tactic: Launch the "Family Network" pool—incentivizing users to onboard aging parents.
- Tactic: Micro-influencer campaigns targeting TikTok/IG health and wellness creators.
Phase 3: Mass Market Scale
$10.5M Months 13-24Focus: Hitting 1,000,000 users. Shifting from direct-to-consumer ad spend to B2B2C API subsidies.
- Hiring: Partner API Integration Specialists.
- Tactic: B2B2C rev-share. We pay third-party health apps to embed the "Connect Health Hive" button.
- Tactic: Broad national performance marketing (Connected TV, Search, Display) leveraging massive LTV/CAC spread.
Monetization Ecosystem
Revenue models that facilitate "abundant consumption" and align incentives across the payer-provider-patient triad.
Investment Note: While our ecosystem supports multiple high-margin revenue streams, our current financial projections (the T2D3 trajectory) are modeled exclusively on our primary business: Secure Compute Data Leases. All other streams represent unmodeled upside.
Secure Compute Data Leases Primary Business
Who Pays: Top 50 Global Pharma, Foundational AI Labs (e.g., OpenAI, Google Health), CROs.
Enterprise buyers don't buy raw data dumps; they lease access to our zero-trust Jupyter notebook environments. This recurring SaaS revenue forms the bedrock of our ARR and is the sole basis for our financial projections.
Clinical Trial Patient Matching
Who Pays: Clinical Research Organizations (CROs), Trial Sponsors, Pharma R&D.
Patient recruitment is the biggest bottleneck in clinical trials, costing billions in delays. Because we have deterministic, real-time EHR and genomic data, we can programmatically identify exact matches for complex trial protocols and securely invite them via their Hive app.
Real-World Evidence (RWE) Syndication
Who Pays: Hedge Funds, Life Science Consultancies, Health Insurers.
Selling fully anonymized, macro-level dashboard access that tracks drug efficacy, off-label usage trends, and market-share shifts in real-time. Similar to a Bloomberg Terminal for biological data.
Consent & Integration API
Who Pays: Third-party digital health apps, Telehealth startups, Wearable OEMs.
Following the "Plaid for Healthcare" playbook. Third-party apps embed the "Connect Health Hive" button to onboard new users instantly with full medical histories, paying us a micro-transaction fee for the data liquidity.
Privacy-First Precision Ad Network
Who Pays: MedTech hardware companies, D2C health brands, Specialized AI health coaches.
Because we hold highly deterministic, verified health data, we offer the most valuable advertising inventory in the world. Advertisers bid to reach specific profiles (e.g., "Type 1 Diabetics using Dexcom") inside the user dashboard, without the raw data ever leaving our secure enclave.
Team Expansion & Tech Infrastructure
Detailed capital allocation from the Strategic Launch Round for aggressively scaling our core engineering, go-to-market, and the secure compute infrastructure required to process billions of health records.
Key Personnel & Hiring Plan
C-Suite & Executive Leadership
Engineering & Data Science (Sandbox Ops)
Go-To-Market (Enterprise & Consumer)
Legal, Compliance & Ethics
Technology & Infrastructure Spend (OPEX/CAPEX)
Cloud & Secure Enclaves
Scaling our AWS/GCP architecture to support zero-trust secure compute environments. Enterprise buyers execute code on our servers; data never leaves the enclave.
Data Integration & API Licensing
Enterprise API licensing costs required to rapidly aggregate user profiles.
Security & Penetration Testing
Continuous, third-party white-hat penetration testing, bug bounty programs, and SOC2/HITRUST compliance auditing.